The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Glioblastoma and Other Malignant Gliomas: A Clinical Review
Abstract
IMPORTANCE: Glioblastomas and malignant gliomas are the most common primary malignant brain tumors, with an annual incidence of 5.26 per 100,000 population or 17,000 new diagnoses per year. These tumors are typically associated with a dismal prognosis and poor quality of life. OBJECTIVE: To review the clinical management of malignant gliomas, including genetic and environmental risk factors such as cell phones, diagnostic pitfalls, symptom management, specific antitumor therapy, and common complications. EVIDENCE REVIEW: Search of PubMed references from January 2000 to May 2013 using the terms glioblastoma, glioma, malignant glioma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and brain neoplasm. Articles were also identified through searches of the authors' own files. Evidence was graded using the American Heart Association classification system. FINDINGS: Only radiation exposure and certain genetic syndromes are well-defined risk factors for malignant glioma. The treatment of newly diagnosed glioblastoma is based on radiotherapy combined with temozolomide. This approach doubles the 2-year survival rate to 27%, but overall prognosis remains poor. Bevacizumab is an emerging treatment alternative that deserves further study. Grade III tumors have been less well studied, and clinical trials to establish standards of care are ongoing. Patients with malignant gliomas experience frequent clinical complications, including thromboembolic events, seizures, fluctuations in neurologic symptoms, and adverse effects from corticosteroids and chemotherapies that require proper management and prophylaxis. CONCLUSIONS AND RELEVANCE: Glioblastoma remains a difficult cancer to treat, although therapeutic options have been improving. Optimal management requires a multidisciplinary approach and knowledge of potential complications from both the disease and its treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Pearce, M. S., Salotti, J. A., Little, M. P., McHugh, K., Lee, C., Kim, K. P., Howe, N. L., Ronckers, C. M., Rajaraman, P., Craft, A. W., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60815-0 · Cited by 3,735
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,330
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium
Bondy, M. L., Scheurer, M. E., Malmer, B., Barnholtz-Sloan, J. S., Davis, F. G., Il'yasova, D., Kruchko, C., McCarthy, B. J., Rajaraman, P., Schwartzbaum, J. A., et al. (2008) · Cancer · doi:10.1002/cncr.23741 · Cited by 932
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Glantz, M. J., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., & Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.10.1886 · Cited by 858
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 840
Weinbaum, C. M., Mast, E. E., & Ward, J. W. (2009) · Hepatology · doi:10.1002/hep.22882 · Cited by 815
Radiotherapy for Glioblastoma in the Elderly
Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J.-S., Jadaud, E., Colin, P., Bondiau, P.-Y., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065901 · Cited by 792
Genome-wide association study identifies five susceptibility loci for glioma
Shete, S., Hosking, F. J., Robertson, L. B., Dobbins, S. E., Sanson, M., Malmer, B., Simon, M., Marie, Y., Boisselier, B., Delattre, J.-Y., et al. (2009) · Nature Genetics · doi:10.1038/ng.407 · Cited by 788
Yung, W. K. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 761
Jakola, A. S., Myrmel, K. S., Kloster, R., Torp, S. H., Lindal, S., Unsgård, G., & Solheim, O. (2012) · JAMA · doi:10.1001/jama.2012.12807 · Cited by 641
Batchelor, T. T., Mulholland, P., Neyns, B., Nabors, L. B., Campone, M., Wick, A., Mason, W., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 614
Clinically relevant drug interactions with antiepileptic drugs
Perucca, E. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02529.x · Cited by 602
Headaches in patients with brain tumors: A study of 111 patients
Forsyth, P. A., & Posner, J. B. (1993) · Neurology · doi:10.1212/wnl.43.9.1678 · Cited by 396
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 384
Porter, K. R., McCarthy, B. J., Freels, S., Kim, Y., & Davis, F. G. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop066 · Cited by 342
Effects of Cell Phone Radiofrequency Signal Exposure on Brain Glucose Metabolism
Volkow, N. D. (2011) · JAMA · doi:10.1001/jama.2011.186 · Cited by 315
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Box, P. (2005) · Dkgest of the World Latest Medical Information · Cited by 299
Atopy and Risk of Brain Tumors: A Meta-analysis
Linos, E., Raine, T., Alonso, A., & Michaud, D. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm170 · Cited by 275
Wick, A., Felsberg, J., Steinbach, J. P., Herrlinger, U., Platten, M., Blaschke, B., Meyermann, R., Reifenberger, G., Weller, M., & Wick, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7722 · Cited by 264
Genome-wide association study of glioma and meta-analysis
Rajaraman, P., Melin, B. S., Wang, Z., McKean-Cowdin, R., Michaud, D. S., Wang, S. S., Bondy, M., Houlston, R., Jenkins, R. B., Wrensch, M., et al. (2012) · Human Genetics · doi:10.1007/s00439-012-1212-0 · Cited by 239
Pitfalls in the diagnosis of brain tumours
Omuro, A. M., Leite, C. C., Mokhtari, K., & Delattre, J.-Y. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70597-x · Cited by 222
Self-citationGibbons, R. J., Smith, S., & Antman, E. (2003) · Circulation · doi:10.1161/01.cir.0000063682.20730.a5 · Cited by 203
Lessons learned in the development of targeted therapy for malignant gliomas
Omuro, A. M. P., Faivre, S., & Raymond, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0047 · Cited by 196
Self-citationA Network Model of a Cooperative Genetic Landscape in Brain Tumors
Bredel, M., Scholtens, D. M., Harsh, G. R., Bredel, C., Chandler, J. P., Renfrow, J. J., Yadav, A. K., Vogel, H., Scheck, A. C., Tibshirani, R., et al. (2009) · JAMA · doi:10.1001/jama.2009.997 · Cited by 192
Glucocorticoid-Induced Hyperglycemia
Kwon, S., Hermayer, K. L., & Hermayer, K. (2013) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31828a6a01 · Cited by 182
Tsao, M. N., Mehta, M. P., Whelan, T. J., Morris, D. E., Hayman, J. A., Flickinger, J. C., Mills, M., Rogers, C. L., & Souhami, L. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.05.024 · Cited by 172
Huber, R., Treyer, V., Schuderer, J., Berthold, T., Buck, A., Kuster, N., Landolt, H., & Achermann, P. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03929.x · Cited by 153
Hardell, L., Carlberg, M., & Mild, K. H. (2012) · Pathophysiology · doi:10.1016/j.pathophys.2012.11.001 · Cited by 144
MRI perfusion in determining pseudoprogression in patients with glioblastoma
Young, R. J., Gupta, A. K., Shah, A. D., Graber, J. J., Chan, T. A.-T., Zhang, Z., Shi, W., Beal, K. P., & Omuro, A. M. P. (2012) · Clinical Imaging · doi:10.1016/j.clinimag.2012.02.016 · Cited by 138
Self-citationSurvey of treatment recommendations for anaplastic oligodendroglioma
Abrey, L. E., Louis, D. N., Paleologos, N. A., Lassman, A. B., Raizer, J. J., Mason, W. P., Finlay, J. L., Macdonald, D. R., DeAngelis, L. M., & Cairncross, J. G. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-002 · Cited by 108
Gilbert, M. R., Dignam, J. J., Won, M., Blumenthal, D. T., Vogelbaum, M. A., Aldape, K., Colman, H., Chakravarti, A., Jeraj, R., Armstrong, T. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.1 · Cited by 105
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro, A. M. P., Chan, T. A.-T., Abrey, L. E., Khasraw, M., Reiner, A. S., Kaley, T. J., DeAngelis, L. M., Lassman, A. B., Nolan, C. P., Gavrilovic, I. T., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos295 · Cited by 102
Self-citationMolecular Epidemiology of Primary Brain Tumors
Gu, J., Liu, Y., Kyritsis, A. P., & Bondy, M. L. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.05.001 · Cited by 94
Maschio, M. C. E., Dinapoli, L., Sperati, F., Pace, A., Fabi, A., Vidiri, A., & Muti, P. C. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0460-x · Cited by 92
Moving toward molecular classification of diffuse gliomas in adults
Theeler, B. J., Yung, W. K. A., Fuller, G. N., & de Groot, J. (2012) · Neurology · doi:10.1212/wnl.0b013e318271f7cb · Cited by 90
Suprarenal Inferior Vena Cava Filters: A 20-Year Single-Center Experience
Kalva, S. P., Chlapoutaki, C., Wicky, S., Greenfield, A. J., Waltman, A. C., & Athanasoulis, C. A. (2008) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2008.03.026 · Cited by 84
Yadav, A. K. (2009) · JAMA · doi:10.1001/jama.2009.1022 · Cited by 70
Update on the management of familial central nervous system tumor syndromes
Hottinger, A. F., & Khakoo, Y. (2007) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-007-0031-5 · Cited by 38
Wick, W., Cloughesy, T. F., Nishikawa, R., Mason, W. P., Saran, F. H., Henriksson, R., Hilton, M., Kerloëguen, Y., & Chinot, O. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2002 · Cited by 35
Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas
Seystahl, K., Wiestler, B., Hundsberger, T., Hertler, C., Wick, W., Weller, M., & Wick, A. (2012) · European Neurology · doi:10.1159/000343811 · Cited by 28
Cited by
Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1024 · Cited by 1,501
Self-citationHanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Sımjee, S. U. (2017) · PubMed · doi:10.22034/apjcp.2017.18.1.3 · Cited by 1,231
De Mattos-Arruda, L., Mayor, R., Ng, C. K. Y., Weigelt, B., Martínez-Ricarte, F., Torrejon, D., Oliveira, M., Arias, A., Raventos, C., Tang, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9839 · Cited by 865
Mutational landscape and clonal architecture in grade II and III gliomas
Suzuki, H., Aoki, K., Chiba, K., Sato, Y., Shiozawa, Y., Shiraishi, Y., Shimamura, T., Niida, A., Motomura, K., Ohka, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3273 · Cited by 831
Jia, G., Han, Y., An, Y., Ding, Y., He, C., Wang, X., & Tang, Q. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.029 · Cited by 753
Metadata
- Authors
- Omuro, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-11-06
- Volume
- 310
- Issue
- 17
- Pages
- 1842
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2134807618
- Cited by
- 2,301
- References
- 53
- FWCI
- 57.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.